An Open-Label, Randomized, Single-Dose, Three-Period, Three-Treatment Crossover Study Assessing the Effect of Food on the Bioavailability of a Single 60-mg Dose of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation(MPH XR-ODT) in Healthy Adults

Trial Profile

An Open-Label, Randomized, Single-Dose, Three-Period, Three-Treatment Crossover Study Assessing the Effect of Food on the Bioavailability of a Single 60-mg Dose of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation(MPH XR-ODT) in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Jan 2018 New trial record
    • 25 May 2017 Results assessing the effect of food on the bioavailability of a single 60-mg dose of a novel extended-release methylphenidate orally disintegrating tablet formulation from the 2 periods of the fed/fasted comparison, published in the Clinical Pharmacology in Drug Development Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top